Advanced search
1 file | 2.75 MB Add to list

Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation

Author
Organization
Abstract
Celecoxib has been effective in the prevention and treatment of chronic inflammatory disorders through inhibition of altered cyclooxygenase-2 (COX-2) pathways. Despite the benefits, continuous administration may increase risk of cardiovascular events. Understanding microbiome-drug-host interactions is fundamental for improving drug disposition and safety responses of colon-targeted formulations, but little information is available on the bidirectional interaction between individual microbiomes and celecoxib. Here, we conducted in vitro batch incubations of human faecal microbiota to obtain a mechanistic proof-of-concept of the short-term impact of celecoxib on activity and composition of colon bacterial communities. Celecoxib-exposed microbiota shifted metabolic activity and community composition, whereas total transcriptionally active bacterial population was not significantly changed. Butyrate production decreased by 50% in a donor-dependent manner, suggesting that celecoxib impacts in vitro fermentation. Microbiota-derived acetate has been associated with inhibition of cancer markers and our results suggest uptake of acetate for bacterial functions when celecoxib was supplied, which potentially favoured bacterial competition for acetyl-CoA. We further assessed whether colon microbiota modulates anti-inflammatory efficacy of celecoxib using a simplified inflammation model, and a novel in vitro simulation of the enterohepatic metabolism. Celecoxib was responsible for only 5% of the variance in bacterial community composition but celecoxib-exposed microbiota preserved barrier function and decreased concentrations of IL-8 and CXCL16 in a donor-dependent manner in our two models simulating gut inflammatory milieu. Our results suggest that celecoxib-microbiome-host interactions may not only elicit adaptations in community composition but also in microbiota functionality, and these may need to be considered for guaranteeing efficient COX-2 inhibition.
Keywords
NONSTEROIDAL ANTIINFLAMMATORY DRUGS, SP-NOV., ACETATE UTILIZATION, BACTERIA, CANCER, HOST, CYCLOOXYGENASE-2, PHARMACOKINETICS, METABOLISM, ACTIVATION

Downloads

  • Hernandez-Sanab-2020-Short-term supplementatio.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.75 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hernandez Sanabria, Emma, et al. “Short-Term Supplementation of Celecoxib-Shifted Butyrate Production on a Simulated Model of the Gut Microbial Ecosystem and Ameliorated in Vitro Inflammation.” NPJ BIOFILMS AND MICROBIOMES, vol. 6, no. 1, 2020, doi:10.1038/s41522-020-0119-0.
APA
Hernandez Sanabria, E., Heiremans, E., Calatayud Arroyo, M., Props, R., Leclercq, L., Snoeys, J., & Van de Wiele, T. (2020). Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation. NPJ BIOFILMS AND MICROBIOMES, 6(1). https://doi.org/10.1038/s41522-020-0119-0
Chicago author-date
Hernandez Sanabria, Emma, Evelien Heiremans, Marta Calatayud Arroyo, Ruben Props, Laurent Leclercq, Jan Snoeys, and Tom Van de Wiele. 2020. “Short-Term Supplementation of Celecoxib-Shifted Butyrate Production on a Simulated Model of the Gut Microbial Ecosystem and Ameliorated in Vitro Inflammation.” NPJ BIOFILMS AND MICROBIOMES 6 (1). https://doi.org/10.1038/s41522-020-0119-0.
Chicago author-date (all authors)
Hernandez Sanabria, Emma, Evelien Heiremans, Marta Calatayud Arroyo, Ruben Props, Laurent Leclercq, Jan Snoeys, and Tom Van de Wiele. 2020. “Short-Term Supplementation of Celecoxib-Shifted Butyrate Production on a Simulated Model of the Gut Microbial Ecosystem and Ameliorated in Vitro Inflammation.” NPJ BIOFILMS AND MICROBIOMES 6 (1). doi:10.1038/s41522-020-0119-0.
Vancouver
1.
Hernandez Sanabria E, Heiremans E, Calatayud Arroyo M, Props R, Leclercq L, Snoeys J, et al. Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation. NPJ BIOFILMS AND MICROBIOMES. 2020;6(1).
IEEE
[1]
E. Hernandez Sanabria et al., “Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation,” NPJ BIOFILMS AND MICROBIOMES, vol. 6, no. 1, 2020.
@article{8653678,
  abstract     = {{Celecoxib has been effective in the prevention and treatment of chronic inflammatory disorders through inhibition of altered cyclooxygenase-2 (COX-2) pathways. Despite the benefits, continuous administration may increase risk of cardiovascular events. Understanding microbiome-drug-host interactions is fundamental for improving drug disposition and safety responses of colon-targeted formulations, but little information is available on the bidirectional interaction between individual microbiomes and celecoxib. Here, we conducted in vitro batch incubations of human faecal microbiota to obtain a mechanistic proof-of-concept of the short-term impact of celecoxib on activity and composition of colon bacterial communities. Celecoxib-exposed microbiota shifted metabolic activity and community composition, whereas total transcriptionally active bacterial population was not significantly changed. Butyrate production decreased by 50% in a donor-dependent manner, suggesting that celecoxib impacts in vitro fermentation. Microbiota-derived acetate has been associated with inhibition of cancer markers and our results suggest uptake of acetate for bacterial functions when celecoxib was supplied, which potentially favoured bacterial competition for acetyl-CoA. We further assessed whether colon microbiota modulates anti-inflammatory efficacy of celecoxib using a simplified inflammation model, and a novel in vitro simulation of the enterohepatic metabolism. Celecoxib was responsible for only 5% of the variance in bacterial community composition but celecoxib-exposed microbiota preserved barrier function and decreased concentrations of IL-8 and CXCL16 in a donor-dependent manner in our two models simulating gut inflammatory milieu. Our results suggest that celecoxib-microbiome-host interactions may not only elicit adaptations in community composition but also in microbiota functionality, and these may need to be considered for guaranteeing efficient COX-2 inhibition.}},
  articleno    = {{9}},
  author       = {{Hernandez Sanabria, Emma and Heiremans, Evelien and Calatayud Arroyo, Marta and Props, Ruben and Leclercq, Laurent and Snoeys, Jan and Van de Wiele, Tom}},
  issn         = {{2055-5008}},
  journal      = {{NPJ BIOFILMS AND MICROBIOMES}},
  keywords     = {{NONSTEROIDAL ANTIINFLAMMATORY DRUGS,SP-NOV.,ACETATE UTILIZATION,BACTERIA,CANCER,HOST,CYCLOOXYGENASE-2,PHARMACOKINETICS,METABOLISM,ACTIVATION}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{12}},
  title        = {{Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation}},
  url          = {{http://dx.doi.org/10.1038/s41522-020-0119-0}},
  volume       = {{6}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: